Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 9/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | MYLK | Q15746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | THPO | P40225 | 3/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454452 | 0.83 | NSD2 (0.71) | NSD2KDM4ECYP3A4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4452891 | 0.82 | NSD2 (0.71) | NSD2KDM4ECYP3A4CYP1A2CYP2D6 | |
| SCHEMBL4483905 | 0.79 | NSD2 (0.69) | NSD2CDK2KDM4EMAPK1ALDH1A1 | |
| SCHEMBL4450789 | 0.79 | EDNRA (0.49) | NSD2EDNRAKMT2A | |
| SCHEMBL4477881 | 0.76 | NSD2 (0.51) | NSD2CDK2KDM4EFABP4 | |
| SCHEMBL4487513 | 0.76 | CA2 (0.60) | NSD2CDK2KDM4ECYP3A4CYP1A2 | |
| SCHEMBL4485514 | 0.76 | NSD2 (0.73) | NSD2KDM4EMEN1KMT2A | |
| SCHEMBL4492415 | 0.75 | ALDH1A1 (0.55) | NSD2CDK2KDM4EEDNRAALDH1A1 | |
| SCHEMBL4483058 | 0.75 | NPY1R (0.49) | NSD2CDK2KDM4EMEN1KMT2A | |
| SCHEMBL4481450 | 0.74 | NSD2 (0.52) | NSD2CDK2KDM4EFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | claimed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | claimed |
| US-7598418-B2 | Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20050215645-A1 | Amide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215645-A1 | Amide derivatives | OGG1, HDAC1, BCL2A1 | NSD2 639/4885CDK2 802/4885KDM4E 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.